Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yong Mi

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Bioorganic Chemistry|August 2, 2023
Neutral ceramidase-active site inhibitor chemotypes and binding modesNicolas Coant, John D Bickel, Ronald Rahaim, et al.
Blood Advances|September 10, 2021
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibitionKaori Saito, Qi Zhang, Haeun Yang, et al.
Frontiers in Oncology|December 20, 2021
Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic LeukemiaYongsheng Ruan, Hye Na Kim, Heather A Ogana, et al.
Nature|May 20, 2011
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibitionCihangir Duy, Christian Hurtz, Seyedmehdi Shojaee, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
A K27-linked Ubiquitin Checkpoint Controls NOTCH HomeostasisBehzad Mansoori, Ying Song, Tian Zhang, et al.
Blood|January 16, 2013
Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapyYao-Te Hsieh, Eun Ji Gang, Huimin Geng, et al.
Nature Medicine|December 4, 2019
A selective BCL-X<sub>L</sub> PROTAC degrader achieves safe and potent antitumor activitySajid Khan, Xuan Zhang, Dongwen Lv, et al.
Leukemia|March 25, 2020
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expressionKristen Fousek, Junji Watanabe, Sujith K Joseph, et al.
Cell Chemical Biology|October 29, 2021
Reprogramming CBX8-PRC1 function with a positive allosteric modulatorJunghyun L Suh, Daniel Bsteh, Bryce Hart, et al.
Blood|March 29, 2020
Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemiaEun Ji Gang, Hye Na Kim, Yao-Te Hsieh, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Bioorganic Chemistry|August 2, 2023
Neutral ceramidase-active site inhibitor chemotypes and binding modesNicolas Coant, John D Bickel, Ronald Rahaim, et al.
Blood Advances|September 10, 2021
Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibitionKaori Saito, Qi Zhang, Haeun Yang, et al.
Frontiers in Oncology|December 20, 2021
Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic LeukemiaYongsheng Ruan, Hye Na Kim, Heather A Ogana, et al.
Nature|May 20, 2011
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibitionCihangir Duy, Christian Hurtz, Seyedmehdi Shojaee, et al.
Biorxiv : the Preprint Server for Biology|December 25, 2025
A K27-linked Ubiquitin Checkpoint Controls NOTCH HomeostasisBehzad Mansoori, Ying Song, Tian Zhang, et al.
Blood|January 16, 2013
Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapyYao-Te Hsieh, Eun Ji Gang, Huimin Geng, et al.
Nature Medicine|December 4, 2019
A selective BCL-X<sub>L</sub> PROTAC degrader achieves safe and potent antitumor activitySajid Khan, Xuan Zhang, Dongwen Lv, et al.
Leukemia|March 25, 2020
CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expressionKristen Fousek, Junji Watanabe, Sujith K Joseph, et al.
Cell Chemical Biology|October 29, 2021
Reprogramming CBX8-PRC1 function with a positive allosteric modulatorJunghyun L Suh, Daniel Bsteh, Bryce Hart, et al.
Blood|March 29, 2020
Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemiaEun Ji Gang, Hye Na Kim, Yao-Te Hsieh, et al.
Pageof 13